Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Phase 2

Conditions: NSCLC Stage IV

Interventions: Drug: GM-CSF
Drug: Sintilimab
Radiation: SBRT

First Posted Date: 2019-09-26

Last Posted Date: 2019-09-26

Lead Sponsor: Fudan University

Target Recruit Count: 63

Registration Number: NCT04106180

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

Phase 2

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Apatinib
Drug: S-1 capsule
Drug: Irinotecan

First Posted Date: 2019-09-24

Last Posted Date: 2019-11-05

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT04101929

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

Sentinel Node Biopsy Vs Observation After Axillary PET

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: SLNB is spared

First Posted Date: 2019-08-28

Last Posted Date: 2020-07-13

Lead Sponsor: Fudan University

Target Recruit Count: 1528

Registration Number: NCT04072653

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

Recruiting

Conditions: Metastases
Neuroendocrine Tumors
Surgery

Interventions: Other: system treatment
Procedure: system treatment and surgery

First Posted Date: 2019-08-26

Last Posted Date: 2019-09-24

Lead Sponsor: Fudan University

Target Recruit Count: 180

Registration Number: NCT04066322

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

FSRT in Breast Cancer Patients With Brain Metastases

Phase 2

Conditions: Breast Cancer
Brain Metastases

Interventions: Radiation: Fractionated stereotactic radiotherapy(FSRT)

First Posted Date: 2019-08-19

Last Posted Date: 2019-08-19

Lead Sponsor: Fudan University

Target Recruit Count: 170

Registration Number: NCT04061408

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Epirubicin
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: 5-fluorouracil
Drug: Docetaxel

First Posted Date: 2019-07-24

Last Posted Date: 2020-04-24

Lead Sponsor: Fudan University

Target Recruit Count: 647

Registration Number: NCT04031703

Patient Report Outcome-Reconstruction and Oncoplastic Cohort

Recruiting

Conditions: Breast Reconstruction
Oncoplastic Breast-conserving Surgery
Breast Cancer
Patient Reported Outcome Measures

Interventions: Procedure: breast reconstruction
Procedure: oncoplastic breast-conserving surgery

First Posted Date: 2019-07-24

Last Posted Date: 2019-07-25

Lead Sponsor: Fudan University

Target Recruit Count: 10000

Registration Number: NCT04030845

Locations: 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China

Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Radiation: Conventional fractionated Radiotherapy
Radiation: Hypofractionated Radiotherapy

First Posted Date: 2019-07-18

Last Posted Date: 2019-07-18

Lead Sponsor: Fudan University

Target Recruit Count: 4052

Registration Number: NCT04025164

Locations: 🇨🇳
Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
🇨🇳
Suzhou Municipal hospital, Suzhou, Jiangsu, China
🇨🇳
The Second Hospital of Dalian Medical University, Dalian, Liaoning, China

and more 2 locations

De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations

Not Applicable

Conditions: Oropharyngeal Carcinoma
De-escalation

Interventions: Other: conventional treatment
Other: Toxicities reduced treatment

First Posted Date: 2019-07-09

Last Posted Date: 2019-07-09

Lead Sponsor: Fudan University

Target Recruit Count: 83

Registration Number: NCT04012502

Locations: 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China

18F-FES PET/CT's Additional Clinical Value in ER+ BC

Completed

Conditions: Breast Cancer

First Posted Date: 2019-07-05

Last Posted Date: 2019-07-05

Lead Sponsor: Fudan University

Target Recruit Count: 19

Registration Number: NCT04006626

Locations: 🇨🇳
Biyun Wang, MD, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy